• Facebook
  • Twitter
  • Instagram
  • Login/Register
  • Terms & Conditions
  • About
  • Expert Panel
  • Contact Us
MYELOMA360
  • Home
  • News
  • Education
    • Conference Coverage
      • ASCO & EHA 2019
      • EHA 2018
      • ASH 2017
    • CME & Webcasts
  • Events
  • Resources
    • Practice Resources
    • Patient Information
      • Product Education
      • Books
  • Videos
Select Page

Ixazomib, Oral Metronomic Cyclophosphamide, and Dexamethasone for First-Line Treatment of Multiple Myeloma: A Phase II Brown University Oncology Group Study

by | Mar 21, 2023 | Publications

Oncologist. 2023 Mar 21:oyad017. doi: 10.1093/oncolo/oyad017. Online ahead of print. ABSTRACT BACKGROUND: Newly diagnosed multiple myeloma patients have many available treatment options. While lenalidomide, bortezomib, and dexamethasone (RVD) is the preferred initial...

Author Correction: Prevalence of smoldering multiple myeloma based on nationwide screening

by | Mar 21, 2023 | Publications

Nat Med. 2023 Mar 20. doi: 10.1038/s41591-023-02308-5. Online ahead of print. NO ABSTRACT PMID:36941333 | DOI:10.1038/s41591-023-02308-5

Evaluation of methods to eliminate analytical interference in multiple myeloma patients with spurious hyperphosphatemia

by | Mar 21, 2023 | Publications

Lab Med. 2023 Mar 21:lmad012. doi: 10.1093/labmed/lmad012. Online ahead of print. ABSTRACT OBJECTIVE: The acid/molybdate assay performed on the Beckman Coulter AU5821 could be subject to paraprotein interference, which potentially results in spurious...

Use of Daratumumab in Patients With Previously Treated Multiple Myeloma

by | Mar 20, 2023 | Publications

J Clin Oncol. 2023 Mar 20:JCO2202850. doi: 10.1200/JCO.22.02850. Online ahead of print. NO ABSTRACT PMID:36940403 | DOI:10.1200/JCO.22.02850

Daratumumab, Bortezomib, and Dexamethasone for Previously Treated Multiple Myeloma

by | Mar 20, 2023 | Publications

J Clin Oncol. 2023 Mar 20:JCO2202665. doi: 10.1200/JCO.22.02665. Online ahead of print. NO ABSTRACT PMID:36940404 | DOI:10.1200/JCO.22.02665

Bone marrow-derived mesenchymal stem cells inhibit NK cell function via Tim-3/galectin-9 in multiple myeloma patients

by | Mar 20, 2023 | Publications

Clin Transl Med. 2023 Mar;13(3):e1224. doi: 10.1002/ctm2.1224. NO ABSTRACT PMID:36938997 | DOI:10.1002/ctm2.1224
« Older Entries
Next Entries »

Recent Content

  • The influencing factors of renal response in newly diagnosed multiple myeloma patients with renal impairment
  • Efficacy and safety of autologous hematopoietic stem cell transplantation pretreated with Melphalan hydrochloride for injection in the treatment of 125 cases of multiple myeloma
  • Dr Deol on the Current Limitations of CAR T-cell Therapy in R/R Myeloma
  • CT-defined body composition as a prognostic factor in multiple myeloma
  • MRD Testing Made a Myeloma Survivor Feel ‘OK to Be Safe’
  • CAR T-Cell Therapy for Multiple Myeloma: Eliminating Disparities Through Accountability
  • Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy
  • Different Translocations of Multiple Myeloma on Fluorescent <em>In Situ</em> Hybridization (FISH) with Clinical Correlation
  • Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy
  • Isatuximab in multiple myeloma
  • Login/Register
  • Terms & Conditions
  • About
  • Expert Panel
  • Contact Us
  • Facebook
  • Twitter
  • Instagram
©2016-2021 MYELOMA360 & MindWrap Medical, LLC
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT